What is Ispecimen?
iSpecimen was founded to bridge the gap between life science researchers requiring human biospecimens and the vast quantities available within healthcare organizations. Its proprietary iSpecimen Marketplace® is designed to streamline and revolutionize the process of biospecimen acquisition, thereby expediting the pace of medical research and innovation. The platform facilitates access to a diverse range of biospecimens, crucial for advancing studies in areas such as disease research, drug development, and diagnostics.
How much funding has Ispecimen raised?
Ispecimen has raised a total of $16.2M across 6 funding rounds:
Series A
$2M
Series B
$8.6M
Debt
$350K
Debt
$1M
Private Equity
$1.8M
Private Equity
$2.5M
Series A (2012): $2M with participation from MassChallenge
Series B (2014): $8.6M led by OneBlood
Debt (2020): $350K supported by PPP
Debt (2024): $1M, investors not publicly disclosed
Private Equity (2025): $1.8M, investors not publicly disclosed
Private Equity (2026): $2.5M, investors not publicly disclosed
Key Investors in Ispecimen
MassChallenge
MassChallenge is a global network of accelerators dedicated to supporting startups across various sectors, including healthcare and life sciences. They provide founders with access to mentorship, resources, and connections crucial for scaling innovative solutions.
OneBlood
OneBlood is a non-profit organization that operates as a blood donation center, supplying vital blood products to hospitals. Their investment in iSpecimen suggests a strategic alignment with entities that facilitate access to biological resources for medical advancement.
What's next for Ispecimen?
With a significant enterprise-level funding context and a recent strategic investment, iSpecimen is well-positioned for its next phase of expansion. The company is likely to leverage this capital to enhance its marketplace technology, broaden its network of healthcare partners, and increase its reach within the global life science research community. Future developments may include expanding data analytics capabilities to provide deeper insights into specimen availability and research trends, further solidifying its market leadership in biospecimen procurement.
See full Ispecimen company page
